AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A 3-hydroxypyridin-4-one compound of formula I:



I

wherein:

R^1 is X with the proviso that R^2 is Y;

or

R^1 is T with the proviso that R^2 is W;

X is C_3-C_6 cycloalkyl;

Y is selected from the group consisting of C_3-C_6 cycloalkyl, C_1 to C_6 alkyl and C_1 to C_6 alkyl monosubstituted with a C_3-C_6 cycloalkyl;

T is C_1 to C_6 alkyl;

W is C_3-C_6 cycloalkyl;

R^3 is selected from the group consisting of hydrogen and C_1 to C_6 alkyl;

R^4 is selected from the group consisting of hydrogen and C_1 to C_6 alkyl;

R^5 is selected from the group consisting of hydrogen and C_1 to C_6 alkyl;

and/or a pharmaceutically acceptable salt thereof.

2. (Original): A compound according to claim 1 wherein R^1 is X with the proviso that R^2 is Y.

3. (Original): A compound of claim 2 wherein X is C_3-C_6 cycloalkyl, Y is C_1 to C_6 alkyl and R^5 is hydrogen or methyl.

4. (Previously Amended): A compound of claim 3 wherein X is cyclopropyl, Y is methyl, R^3 is hydrogen, R^4 is methyl and R^5 is hydrogen, and wherein said compound is 1-cyclopropyl-3-hydroxy-6-methyl-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid methylamide.

5. (Original): A pharmaceutical composition comprising 1-cyclopropyl-3-hydroxy-6-methyl-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid methylamide and a pharmaceutically acceptable carrier.

6. (Previously Amended): The pharmaceutical composition of claim 5 which is adopted for oral administration.

7. (Original): A compound of claim 2 wherein X is C_3-C_6 cycloalkyl, Y is C_3-C_6 cycloalkyl and R^5 is hydrogen.

8. (Previously Amended): A compound of claim 7 wherein X is cyclopropyl, Y is cyclopropyl, R^3 is hydrogen, R^4 is methyl, and wherein said compound is *N*,1-dicyclopropyl-3-hydroxy-6-methyl-4-oxo-1,4-dihydropyridine-2-carboxamide.

9. (Previously Amended): A compound of claim 3 wherein X is cyclopropyl, Y is methyl, R^3 is hydrogen, R^4 is methyl and R^5 is methyl, and wherein said compound is 1-cyclopropyl-3-hydroxy-*N*,*N*,6-trimethyl-4-oxo-1,4-dihydropyridine-2-carboxamide.

10. (Original): A compound according to claim 1 wherein R^1 is T with the proviso that R^2 is W.

11. (Original): A compound of claim 10 wherein T is C_1-C_6 alkyl and W is C_3-C_6 cycloalkyl.

12. (Previously Amended): A compound of claim 11 wherein T is methyl, W is cyclopropyl, R^3 is hydrogen, R^4 is methyl and R^5 is hydrogen, and wherein said compound is 3-hydroxy-1,6-dimethyl-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid cyclopropylamide.

13. (Cancelled).

14. (Cancelled).

15. (Cancelled).

16. (Original): A pharmaceutical composition comprising a compound according to claim 1 and a physiologically acceptable carrier.

17. (Original): A pharmaceutical composition according to claim 16, which is adopted for oral administration.

18. (Previously Amended): A method of treating at least one medical condition related to a toxic concentration of iron comprising administering to an animal suffering from said condition a therapeutically effective amount of the compound of claim 4, wherein said at least one medical condition is selected from the group consisting of thalassaemia, sickle cell disease and haemochromatosis.